reports
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces the Voting Results of December 2025 Extraordinary Gen...
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting 37.8% of voting rights present or representedAll resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share ...
ORYZON Presents Data for Iadademstat Combinations in AML at the Americ...
ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting 100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 months and good tolerability70% of patients derived to Hematopoietic Stem Cell Transplantation (HSCT) 67% CCR at the expansion dose in study evaluating iadademstat plus gilterinib in FLT3-mutated relapsed/refractory AML patients; 47% CR+CRhTreatment was safe and well tolerate...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Reports Financial Results and Corporate Update for Quarter Ende...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025 The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS(Vafidemstat) Received feedback from the FDA on Phase III PORTICO-2 trial in BPD; Company to revise protocol and resubmitReinforcing company’s clinical, strategy and regulatory teamsExpansion of ongoing Phase IIb in schizophrenia into other EU countries continuesPreparations continue for new Phase II trial in aggression in Autism Spec...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025
ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025 Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual MeetingPreliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rateUpdated preliminary data from the ongoing Phase Ib FRIDA trial evaluating iadademstat in combination with gilteritinib in FLT3-mutated relapsed/refractory AML showed a 67% response rate in the expanded dose, superior to both historical and real-world...
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of I...
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCDIadademstat has demonstrated a favorable safety and tolerability profile across ~200 patients in prior oncology clinical trials MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics, today ...
ORYZON to Participate in Upcoming Events in November
ORYZON to Participate in Upcoming Events in November MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO-EUROPE, November 3-5Location: Viena Congress and Convention Center, Vienna, Austria LSX Investival Showcase Europe 2025, November 17Location: Old Billingsgate, London, United Kingdom Jefferies Global Healthcare Conference, November 17-20Location: ...
ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Ima...
ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programsTo bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, is pleased to announce the strategic collaboration with Dr. Iman Barilero, PharmD, PhD, as Senior...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Receives Feedback From the FDA in Response to the Submitted Pha...
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder Provides clarity on the aspects to incorporateCompany to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the Phase III protocol to evaluate vafidemstat in bor...
ORYZON Strengthens Patent Portfolio for iadademstat with European Gran...
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application EP20712594.9, entitled “Combinations of iadademstat for cancer therapy”. The allowed claims protect the use of iadademstat in combination with PD1 or P...
ORYZON to Participate in Upcoming Events in September and October
ORYZON to Participate in Upcoming Events in September and October MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at the following upcoming events: Drug Discovery Innovation Programme, September 25-26Location: Intercontinental Hotel, Barcelona, Spain Paris Midcap Event 2025, September 30-October 1Location: Four Seasons George V, Paris, France BME Investor Access Event 2025, October 7Lo...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat wi...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant In Australia and Europe MADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it continues to expand its patent portfolio for iadademstat and vafidemstat, Oryzon’s clinical-stage LSD1 inhibitors for oncology and central nervous system (CNS) disorders, following new Decisions to Grant from the Australian and European patent office...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Finalist at the 2025 European Lifestars Awards
ORYZON Finalist at the 2025 European Lifestars Awards In the Category Post-IPO Raise of the Year MADRID, Spain and CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has been selected as a Finalist in the 2025 European Lifestars Awards in the category Post-IPO Raise of the Year for the European Mediterranean region. The Lifestars Awards bring together leading figures from across the European life sciences industry, in...
ORYZON Receives European Medicines Agency Approval to Initiate a Phase...
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND, to initiate a Phase Ib trial of iadademstat in ...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Reports Financial Results and Corporate Update for Half-Year En...
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025 Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1.8 M from R&D cash-back incentives)Company has terminated the Convertible Bonds financing facility with Nice&GreenClinical trial protocol for vafidemstat’s Phase III PORTICO-2 trial in BPD submitted to the FDAExpansion of ongoing Phase IIb EVOLUTION study with vafidemstat in schizophrenia into other EU coun...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.